<?xml version="1.0" encoding="UTF-8"?>
<p>
 <xref ref-type="fig" rid="F0005">Figure 5(A)</xref> displays the BOILED-Egg graph of the WLOGP vs. TPSA (topological polar surface area) for spirooxindole 
 <bold>6a</bold>
 <xref rid="CIT0037" ref-type="bibr">
  <sup>37</sup>
 </xref>, where it is located in the region of human intestinal absorption (HIA) with no BBB permeability so it is anticipated to display low occurrence for CNS side effects. Also, this graph revealed that spirooxindole 
 <bold>6a</bold> is not a P-glycoprotein substrate (PGPâˆ’), therefore it is not susceptible to the efflux mechanism carried out by this transporter that utilised by many cancer cell lines as a drug-resistance mechanism
 <xref rid="CIT0038" ref-type="bibr">
  <sup>38</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0039" ref-type="bibr">
  <sup>39</sup>
 </xref>. 
 <xref ref-type="fig" rid="F0005">Figure 5(B)</xref> represents the bioavailability radar chart for spirooxindole 
 <bold>6a</bold>, which consists of six axes for six key properties for oral bioavailability; polarity (POLAR), solubility (INSOLU), lipophilicity (LIPO), flexibility (FLEX), saturation (INSATU) and size (SIZE) 
 <xref rid="CIT0039" ref-type="bibr">
  <sup>39</sup>
 </xref>
 <sup>,</sup>
 <xref rid="CIT0040" ref-type="bibr">
  <sup>40</sup>
 </xref>. The range for optimal property values is displayed as a pink area, whereas the red line represents the predicted properties for the examined molecule.
</p>
